Michael R Hayden

USPTO Granted Patents = 21 (Patent Applications = 17)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 208(Granted Patents)

Company Filing History:

13 out of 932

The University of British Columbia

patents

6 out of 109

Xenon Pharmaceuticals Inc.

patents

4 out of 4,123

Wisconsin Alumni Research Foundation

Isis Pharmaceuticals, Inc.

patents

6. 1 out of 5

Hsc Research and Development Limited

patents

7. 1 out of 1

Aspreva Pharmaceuticals S.a.

patent

8. 1 out of 1

Aspreva Pharmaceuticals Corp.

patent

9. 2 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2020

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10731160 - Allele-specific therapy for Huntington disease haplotypes (2020-08-04),

2. 10533172 - Allele-specific therapy for huntington disease haplotypes (2020-01-14),

3. 9290751 - LPL variant therapeutics (2016-03-22),

4. 9157120 - Methods and compositions for the treatment of huntington's disease (2015-10-13),

5. 9006198 - Selective reduction of allelic variants (2015-04-14),

6. 8957071 - Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors (2015-02-17),

7. 8715968 - Methods and reagents for modulating cholesterol levels (2014-05-06),

8. 8679750 - Methods and compositions for the treatment of Huntington'S disease (2014-03-25),

9. 8067219 - Polynucleotide encoding an ATP binding cassette transporter 1 (ABC1) polypeptide (2011-11-29),

10. 7816075 - Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents (2010-10-19),

11. 7785886 - Methods and reagents for modulating cholesterol levels (2010-08-31),

12. 7696151 - Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents (2010-04-13),

13. 7166584 - Cholesterol transport gene (2007-01-23),

14. 6987001 - Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents (2006-01-17),

15. 6814962 - Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same (2004-11-09),

Sure, here is the article about inventor Michael R Hayden:

Title: Innovator Spotlight: Michael R Hayden - Pioneering Allele-Specific Therapy for Huntington Disease

Introduction:

Michael R Hayden is a prolific inventor based in Vancouver, Canada, with a remarkable portfolio of 21 patents to his name. His groundbreaking work in the field of developing allele-specific therapies for Huntington disease has earned him global recognition in the medical research community.

Latest Patents:

Among his latest patents is the "Allele-specific therapy for Huntington disease haplotypes." This innovative invention focuses on compositions and methods to inhibit mutant HTT mRNA transcription or CAG-expanded HTT protein expression in cells. By targeting differentiating polymorphisms such as rs72239206 and rs363107, Hayden's oligomer sequences offer promising avenues for personalized treatments.

Career Highlights:

Having worked at renowned institutions like the University of British Columbia and Xenon Pharmaceuticals Inc., Hayden's career exemplifies a steadfast commitment to translational research. His dedication to bridging the gap between laboratory discoveries and clinical applications has been instrumental in advancing the field of genetic therapies.

Collaborations:

Throughout his career, Hayden has collaborated with esteemed colleagues such as Simon N Pimstone and Mark Gray-Keller. Their collective efforts have synergized innovative thinking and expertise, leading to impactful developments in precision medicine for neurodegenerative disorders.

Conclusion:

In conclusion, Michael R Hayden's contributions to the field of genetic therapies, particularly in addressing Huntington disease, underscore his visionary approach to healthcare innovation. With a legacy of patents shaping the future of precision medicine, Hayden continues to inspire the next generation of inventors and researchers worldwide.

This text is generated by artificial intelligence and may not be accurate.